TPI 287: Phase II started

Cortice began a 2-stage, open-label, dose-escalation, U.S. Phase II trial of IV TPI 287 every 3 weeks plus 10 mg/m 2 IV Avastin bevacizumab every 2 weeks in 6-week cycles in about 18 patients with re...